New pill may extend remission in advanced ovarian cancer
NCT ID NCT04169997
First seen Jan 29, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests a drug called IMP4297 (a PARP inhibitor) as a maintenance treatment after first-line chemotherapy for people with advanced ovarian cancer. The goal is to see if it can delay cancer progression. About 404 participants are randomly assigned to receive either IMP4297 or a placebo. This is a phase 3 trial, meaning it is in the final stage of testing before possible approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
-
Sun Yat-sen University Cancer Center
Guanzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.